Retained Products of ConceptionMiscarriageConservative Management
Study summary
The goal of this observational study is to learn about the therapeutic effects of the conservative treatment approach on pepole with retained products of conception (RPOC) and Enhanced myometrial vascularity (EMV).
The main question it aims to answer is: Is it possible to achieve the natural resolution of RPOC by combining it with EMV through conservative treatment？ Participants will receive conservative treatment (such as mifepristone, GnRH-a, or expectant management) following the initial diagnosis of RPOC and EMV, and the therapeutic efficacy of the conservative approach will be assessed after the completion of two menstrual cycles.
Eligibility
Sex
FEMALE
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Recent history of miscarriage or delivery (within the past 8 weeks)
* Strong willingness to undergo conservative management
* Hemodynamically stable
* Signed informed consent form
Exclusion Criteria:
* Heavy vaginal bleeding (requiring immediate surgical intervention)
* Active pelvic or systemic infection (e.g., fever \>38°C, elevated CRP/WBC)
* Severe dysfunction of vital organs (heart, liver, or kidney)
* Known drug allergies or contraindications to proposed medications (e.g., misoprostol intolerance)
* Suspected ectopic pregnancy or gestational trophoblastic disease (confirmed by ultrasound or β-hCG levels)
* Placenta accreta spectrum disorders diagnosed during current pregnancy
* History of uterine artery embolization
Primary outcome measure(s)
The disappearance rate of RPOC — After conservative treatment, transvaginal ultrasound was performed at the end of the second menstrual cycle (calculated from the first day of menses, 28-30 days per cycle) to assess RPOC resolution The definition of "the disappearance rate of RPOC" refers to the absence of significant residual trophoblastic tissue as indicated by ultrasound examination
Trial sites (1)
Facility
City
Region
Status
Hysteroscopy Center, Fuxing Hospital, Capital Medical University
Beijing
China
Recruiting
More Fu Xing Hospital, Capital Medical University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.